Home » Newsletters » BioWorld Science

BioWorld Science

May 30, 2007

View Archived Issues

Promising preclinical results of novel Yellow fever virus vaccine

Recombinant CD outer membrane protein is a promising vaccine candidate against Moraxella infection

Promising preclinical results of novel gene therapy against Niemann-Pick disease

Preclinical snapshots of the 68th Annual Meeting of the Society for Investigative Dermatology

Preclinical studies presented at ECTS

Basic research on novel drugs reported at the 103rd ATS conference

Novel therapeutic agents for neurological disorders disclosed in recent patents

Kitasato Institute and Aphoenix patent novel compounds for colitis

Data presented on p16INK4a biomarker for cervical dysplasia

BG Medicine and M.D. Anderson collaborate on breast cancer biomarkers

Recent patents disclose novel antipsychotic and anxiolytic agents

In vitro results of UK-500,001, Pfizer's novel PDE4 inhibitor for the treatment of COPD

EpiStem begins biomarker feasibility studies with AstraZeneca

VR1 antagonist GRC-6211 completes phase I trials in Europe

Recent patents describe new therapeutic agents for diabetes

Further clinical data on ambrisentan in pulmonary hypertension presented

Japanese approval for omeprazole 10 mg in nonerosive GERD

Bionomics selects BNC-210 as drug candidate for psychiatric disorders

New trial explores Reolysin with paclitaxel and carboplatin in advanced cancers

SD-118 begins phase I trials for neuropathic pain

Advisory Committee meeting set to review of Tysabri for Crohn's disease

Swissmedic grants accelerated assessment of planned application for ceftobiprole

FDA approval for Xyzal

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...